Xencor has received an undisclosed amount as the milestone payment from Janssen for the use of Xtend antibody technology platform.
Xencor president and CEO Bassil Dahiyat said, "There has been significant interest in Xtend technology because of the impact it has on the pharmacokinetic properties of antibodies, and we are seeing Xencor technology license agreements with partners translate into promising pipeline programs."
The Xtend antibody technology leverages its series of antibody Fc variants to prolong the serum half-life of immunoglobulin molecules thereby increasing the performance of the antibody against various therapeutic indications.